<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[이엔셀 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=32381></link><description><![CDATA[이엔셀 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 18:27:26 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2019/01/12_31335338_20190116102252_8021157316.gif]]></url></image><language>ko-KR</language><item><title><![CDATA[ENCell Presents the Phase 1 Clinical Trial Results of EN001 for Charcot-Marie-Tooth Disease at the PNS conference]]></title><link>https://www.newswire.co.kr/newsRead.php?no=992387</link><description><![CDATA[SEOUL--(Korea Newswire)--ENCell Co., Ltd., a biotech in South Korea specializing in Cell and Gene therapy (CGT), presented promising results from their First-in-Human Phase 1 clinical trial of the novel mesenchymal stem cell therapy (EN001) for Charcot-Marie-Tooth disease type 1A (CMT1A) at the Peripheral Nerve Society (PNS) annual meeting in Montreal on June 23, 2024. ...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2024/06/31017998_20240627135429_3005009456.jpg]]></url></image><pubDate>Thu, 27 Jun 2024 13:58:49 +0900</pubDate></item><item><title><![CDATA[이엔셀, 한미약품의 항암 유전자 줄기세포치료제 위탁생산]]></title><link>https://www.newswire.co.kr/newsRead.php?no=882143</link><description><![CDATA[서울--(뉴스와이어)--이엔셀은 한미약품과 최근 ‘항암 유전자 줄기세포치료제(HM21001)’ 위탁생산(CMO) 계약을 체결하고 임상시험용 의약품을 생산 중이라고 17일 밝혔다.  HM21001은 한미 오픈이노베이션 전략의 일환으로 한미약품이 2016년 아주대학교 서해영 교수팀의 기술을 도입해 공동 개발하는 골수유래 중간엽 줄기세포를 사용한 교모세포종(GBM) 유전자세포치료제이다.  이엔셀은 이번 ...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2019/01/3698601005_20190116145146_7522563373.jpg]]></url></image><pubDate>Thu, 17 Jan 2019 09:00:00 +0900</pubDate></item></channel></rss>